Problem solving, impulse control and planning in patients with early- and late-stage Huntington’s disease by Sabrina Mörkl et al.
1 3
Eur Arch Psychiatry Clin Neurosci (2016) 266:663–671
DOI 10.1007/s00406-016-0707-4
ORIGINAL PAPER
Problem solving, impulse control and planning in patients 
with early- and late-stage Huntington’s disease
Sabrina Mörkl1 · Nicole J. Müller1 · Claudia Blesl1 · Leonora Wilkinson2 · 
Adelina Tmava1 · Walter Wurm1 · Anna K. Holl1 · Annamaria Painold1 
Received: 11 January 2016 / Accepted: 11 June 2016 / Published online: 2 July 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
and number of breaks do not. Striatal degeneration, which 
is a characteristic feature of the disease, might not affect all 
aspects of executive function in HD.
Keywords Huntington’s disease · Executive function · 
Tower of London · Neuropsychology · Disease severity
Introduction
Neuropsychological deficits caused by neurodegenerative 
conditions, such as dementia, multiple sclerosis, amyotrophic 
lateral sclerosis and Huntington’s disease (HD), significantly 
impair patients’ abilities and affect their quality of life [1–4].
HD is an autosomal-dominant trinucleotide repeat disor-
der with early signs of cognitive deterioration. The under-
lying defect in HD is an elongated gene, which produces 
a protein called huntingtin, leading to neural apoptosis 
especially in the striatum. In patients with HD, cognitive 
dysfunction may precede the first neurologic signs by up to 
10 years [5–7]. The first signs of cognitive dysfunction are 
usually the deterioration of executive functions and psycho-
motor speed, which are prominent signs in the preclinical 
stages and in early disease stages. This ‘frontal’ pattern of 
cognitive deterioration in HD is considered to result from 
early neuronal death in the caudate, which leads to dys-
function in fronto-striatal circuits [8]. Several MRI studies 
showed consistent degeneration of the striatum (caudate 
nucleus and putamen) already in presymptomatic patients 
[9–11] and in symptomatic stages of the disease [5, 12].
Due to this progressive degeneration in specific parts of 
the brain, it has been assumed that clinical features would 
decrease linearly too. While several studies on the impair-
ment of cognitive functions in prodromal and early stages 
of the disease have been conducted [5–7, 13–15], cognitive 
Abstract  Sub-domains of executive functions, including 
problems with planning, accuracy, impulsivity, and inhibi-
tion, are core features of Huntington’s disease. It is known 
that the decline of cognitive function in Huntington’s disease 
is related to the anatomical progression of pathology in the 
basal ganglia. However, it remains to be determined whether 
the severity of executive dysfunction depends on the stage 
of the disease. To examine the severity of sub-domains of 
executive dysfunction in early- and late-stage Huntington’s 
disease, we studied performance in the Tower of London 
task of two groups of Huntington’s disease patients (Group 
1: early, n = 23, and Group 2: late stage, n = 29), as well 
as a third group of age, education, and IQ matched healthy 
controls (n = 34). During the task, we measured the total 
number of problems solved, total planning time, and total 
number of breaks taken. One aspect of executive function 
indexed by the number of solved problems seems to pro-
gress in the course of the disease. Late-stage Huntington’s 
disease patients scored significantly worse than early-stage 
patients and controls, and early-stage patients scored sig-
nificantly worse than controls on this measure of accuracy. 
In contrast, late- and early-stage HD patients did not differ 
in terms of planning time and number of breaks. Early- and 
late-stage HD pathology has a different impact on executive 
sub-domains. While accuracy differs between early- and 
late-stage HD patients, other domains like planning time 
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function in late stages has been assessed rarely. The pres-
ence of increasing neuronal cell loss especially in the stria-
tum is expected to lead to global dementia, and it follows 
that late-stage patients should therefore show a pathologic 
performance on all cognitive functions.
However, this assumption was called in question by 
studies that reported a nonlinear degeneration of some cog-
nitive functions. Beste et al. [16] reported in their study on 
the assessment of auditory sensory memory that sympto-
matic HD patients performed better than presymptomatic 
HD patients and healthy controls on an auditory signal 
detection task. They proposed that the better performance 
of symptomatic patients occurred due to an increased activ-
ity of the NMDA receptor system, which occurs regularly 
in patients experiencing neuronal cell death. Papoutsi et al. 
[15] highlighted that it is unknown if the development of 
cognitive decline is comparable with that of topographi-
cal changes of the striatum. They also suggested that cog-
nitive decline may be compensated at a certain point and 
that brain changes and cognitive changes may not develop 
simultaneously. Due to the small number of studies on cog-
nitive function in severe stages of HD, it remains unclear 
whether all aspects of cognitive function are worse in late-
stage HD patients compared to early-stage HD patients.
The Tower of London (ToL) [17] is a neuropsychological 
test, sensitive to executive functions like mental problem solv-
ing, planning, behavioural inhibition, and impulse control. The 
executive function problem solving (accuracy) is measured by 
the total number of solved problems in four levels of diffi-
culty. Behavioural inhibition or impulse control is reflected by 
the measure of planning time (in other studies also called reac-
tion time or latency), which is the time from the presentation 
of the start board to the first movement. The number of breaks 
(pausing during the process of problem solving) is an indica-
tor for problem reflection and planning. Particularly, patients 
with affections of the frontal lobe tend to rash and impulsive 
decisions. This behaviour is a sign of increased impulsivity 
and decreased ability of self-control [17].
Participants are given a start and a goal board containing 
three pegs of descending lengths and three balls; they are 
instructed to transform the start board ball arrangement to 
the goal board ball arrangement using the smallest number 
of single-ball movements possible and observing various 
limitations (Fig. 1).
The ToL has been used in one study of early-stage HD 
patients [18] and in one study of both presymptomatic and 
early patients [19]. Watkins and colleagues reported signifi-
cantly worse performance of early-stage HD patients relative 
to controls for the problem solving during the so-called ‘one-
touch’-ToL, which is a modified version of the ToL, that min-
imizes motor demands of the task [18]. In an fMRI adapted 
version of the task, Unschuld et al. [19] reported a signifi-
cantly worse accuracy in early-stage HD patients relative 
to controls but no significant differences between the three 
groups for planning time. As both of the above studies of 
ToL performance in HD were conducted with early-stage HD 
patients, their findings do not inform us how late-stage HD 
patients would score on the task. If the topographical changes 
of the striatum associated with the late stage of the disease are 
directly related to the decline of executive function, it follows 
that accuracy and reaction time should be severely impaired, 
in late-stage HD patients relative to controls and early-stage 
patients. In contrast, if accuracy and planning time would 
not differ between early- and late-stage HD patients, then it 
would indicate that other neurophysiological substrates might 
contribute to balance executive dysfunctions due to neuronal 
cell death in the caudate in HD. With respect to the ToL, there 
are two potential outcomes for late-stage HD patients: I) pre-
suming that cognitive functions deteriorate linearly and that 
cognition worsens according to the topographical changes in 
the striatum; we would expect a significantly worse result for 
accuracy and a much longer reaction time in late-stage HD 
patients relative to controls and early-stage patients as well 
combined with a significant but less robust impairment of 
performance in early-stage patients relative to controls. II) If 
we presume that the development of cognitive decline is not 
comparable with that of topographical changes of the stria-
tum, we may find any other results in severe HD patients as 
well as in those with early stage.
The aim of the present study was to examine sub-aspects 
of executive functioning in early-stage and late-stage HD. 
We assessed both groups of HD patients using the ToL task; 
this included an assessment of number of solved problems, 
planning time and number of breaks. In early-stage HD it 
is established that in preclinical stage, HD gene mutation 
carriers are nearly free of symptoms, regardless of the 
existence of neurodegeneration. Functional brain imaging 
studies suggest a neural compensation in early-stage HD, 
Fig. 1  Illustration of the ToL 
task—example for a two-move 
problem
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where the brain, in response to neurodegeneration, devel-
ops mechanisms of functional reorganization in order to 
maintain cognitive performance [15, 20]. We hypothesized 
that executive functions would partially differ between the 
early- and late-stage HD group.
Methods
Participants
Fifty-two patients (32 male) with genetically proven HD aged 
between 25 and 69 (M = 47.69, SD = 11.20) were studied. 
The patients were recruited from the HD clinic at our Depart-
ment of Psychiatry. Patients were in stage one to stage four 
of the disease, rated with Shoulson’s clinical stages [21]. To 
compare early affected patients with those in later stages, 
we divided them into two groups based on disease severity: 
early-stage group (stage 1 and 2, n = 23, male = 15) and late-
stage group (stage 3 and 4, n = 29, male = 17). As stage divi-
sion according to the clinical stages of Shoulson [21] depends 
on a number of clinical characteristics, disease duration alone 
is not used to divide the patients in an early- and late-stage 
group. Therefore, individual early- and late-stage HD patients 
could have a similar duration of illness.
The Unified Huntington’s Disease Motor Score Rating 
Scale (UHDRS motor) [22] was employed for the assess-
ment of motor symptoms. The UHDRS cognitive score 
was calculated as the sum of the scores of the verbal flu-
ency test, the symbol digit modalities test, and the Stroop 
test (Stroop colour, words, and inhibition) [22]. The total 
functional capacity (TFC) and the mini-mental state exami-
nation (MMSE) were assessed in all patients. Disease 
duration ranged from 1 to 7 years (M = 2.48, SD = 2.00) 
in the early-stage group and from 1 to 17 years (M = 6.93, 
SD = 4.33) in the late-stage group. All patients presented 
with a positive genetic test for the HD gene with a CAG 
repeat expansion between 40 and 58. For all patients, an 
estimate of premorbid IQ was obtained with the MWT-B 
(Mehrfachwahl-Wortschatz-Intelligenz test) [23].
At the time of testing, 32/52 patients were treated with 
disease-related medication. Two late-stage HD patients were 
treated with antipsychotics, mainly for treatment of choreatic 
movements and personality changes, 19 were treated with 
a combination of antipsychotics and antidepressants (one 
early-stage patient and 18 late-stage patients), and 11 were 
treated with antidepressants (nine early-stage HD patients 
and two late-stage HD patients). None of the patients 
showed any signs of depression at the time of assessment. 
Seven early-stage HD patients and 15 late-stage HD patients 
had previous major depression, five early-stage HD and five 
late-stage HD patients had previous minor depression.
Thirty-four healthy volunteers (19 male) aged between 
18 and 77 (M = 49.06, SD = 17.38) took part in the 
study. Controls were recruited at the Campus of the Karl-
Franzens-University and at the Medical University of Graz 
through word of mouth and flyers posted on the university 
campus. Prior to participation, they were screened for suit-
ability. None of the medication-free controls had any neu-
rological disorder, psychiatric illness, head injury, or his-
tory of alcohol or drug abuse. For all patients and controls, 
comorbid psychiatric diagnoses have been excluded in a 
diagnostic interview which was performed by our experi-
enced consultant psychiatrist (AH).
Information about controls and HD patients is presented 
in Table 1. The study was approved by the local Ethics 
Table 1  Demographic information for patients with early- and late-stage Huntington’s disease (HD) and controls and clinical characteristics of 
the patients
SD standard deviation, NS not significant







Mean (SD) Mean (SD) Mean (SD)
Age (years) 49.21 (11.13) 45.78 (11.23) 49.06 (17.38) .62
Education (years) 12.24 (1.73) 12.00 (2.32) 12.44 (2.76) .78
Male/female participants 17/12 15/8 19/15 .88
Disease duration (years) 6.93 (4.33) 2.48 (2.00) <.001
Genetic burden score 481.50 (106.47) 413.52 (90.41) .03
CAG repeats 46.30 (4.87) 45.45 (3.74) .52
Mini-mental state examination (0–30) 23.79 (4.38) 26.90 (3.43) .02
Premorbid IQ 104.17 (13.83) 108.39 (11.13) .33
Unified Huntington’s disease motor score rating scale (0–124) 38.76 (14.70) 20.04 (13.46) <.001
Unified Huntington’s disease cognitive rating scale 128.54 (49.25) 210.22 (69.13) <.001
Total functional capacity (0–13) 6.29 (2.72) 11.39 (2.39) <.001
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Committee of our Medical University. Informed consent 
was obtained prior to participation in the study from all 
participants.
Methods
We used the German version of the ToL [17]. In the stand-
ard version of this task [24], participants are given two 
boards (start board and goal board), each board containing 
three pegs of descending lengths and three balls: one red, 
one yellow, and one blue ball. Participants are instructed to 
transform the start board ball arrangement to look exactly 
like the goal board ball arrangement using the smallest 
number of single-ball movements possible. There is only 
one correct approach for each task. There are several lim-
itations on the ball movements: it is not allowed to place 
more balls on a peg than it can hold; there cannot be more 
than one ball off a peg at the same time; and a ball cannot 
be moved if it is underneath another ball. Participants were 
told not to start until they had found the right solution.
Participants had to solve four sets of each five tasks of 
increasing difficulty (three-move problems, four-move prob-
lems, five-move problems, and six-move problems). For this 
study, we recorded if participants were able to arrange the 
balls with the smallest number of ball movements. A task 
was only considered as correct if the participant managed 
to use the smallest number of movements. Additionally, the 
planning time and the number of breaks were recorded.
Results
Participants
The groups of late-stage HD, early-stage HD and controls 
were matched for age [F(2,83) = .48, p = .62], education 
[F(2,83) = .25, p = .78], IQ [F(2,83) = .99, p = .33], and sex 
[χ2(2) = .50, p = .88].
Number of solved problems
Figure 2 depicts the number of solved problems for three, 
four, five, and six-move problems of the ToL plotted sep-
arately for the three groups. To determine the effect of 
HD disease severity on accuracy during the ToL task, an 
ANOVA was performed on mean number of solved prob-
lems with level of Difficulty (three-move problem vs. 
four-move problems vs. Five-move problems vs. six-move 
problems) as a within-subjects variable and Group as a 
between-group variable (late-stage HD vs. early-stage 
HD vs. controls). This analysis revealed significantly 
main effects of Difficulty [F(3,249) = 76.85, p < .001], 
Group [F(2) = 24.93, p < .001], and a significant interac-
tion between Group x Difficulty [F(6,249) = 4.87, p < .001]. 
Therefore, the performance of all three groups across all 
four levels of difficulty was significantly different.
In light of the significant interaction between Group 
x Difficulty, we compared the mean number of solved 
problems between each of the three groups and at each of 
the four levels of difficulty in performing a post hoc test 
(Tukey). For the comparison between early- and late-stage 
HD patients, a significant difference was found in follow-
ing conditions: three-move problems [Tukey; p = .04], 
four-move problems [Tukey; p = .02], five-move problems 
[Tukey; p = .03], and six-move problems [Tukey, p < .001]. 
For the comparison between controls and late-stage HD 
patients in all four conditions, late-stage HD patients 
scored significantly worse relative to controls (three-move 
problems [Tukey, p < .001]; four-move problems [Tukey, 
p < .001], five-move problems [Tukey, p < .001], and six-
move problems [Tukey, p < .001]). In the comparison 
between early-stage HD patients and controls, early-stage 
Fig. 2  Number of solved prob-
lems for three-, four-, five- and 
six-move problems, plotted for 
late-stage HD patients, early-
stage HD patients and controls. 
Error bars represent standard 
errors. Asterisks indicate where 
the comparison between the 
groups was significant. *p < .05
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HD patients scored significantly worse in following condi-
tions: four-move problems [Tukey, p = .05] and six-move 
problems [Tukey, p = .03]).
Planning time
Figure 3 shows the total planning time for three-, four-, 
five-, and six-move problems of the ToL plotted sepa-
rately for the three groups. To determine the effect of 
HD disease severity on planning time, an ANOVA was 
performed with Difficulty as a within-subjects vari-
able and Group as a between-group variable. This anal-
ysis revealed significantly main effects of Difficulty 
[F(3,249) = 28.81, p < .001], Group [F(2) = 4.11, p = .02], 
and a significant interaction between Group × Difficulty 
[F(6,249) = 5.61, p < .001].
In light of the interaction between Group × Difficulty, 
we compared the mean planning time between each of the 
three groups and at each of the four levels of difficulty. 
For the comparison between controls and early-stage HD 
patients, a significant difference was found in the plan-
ning time of three-move problems [Tukey, p = .02], where 
early-stage patients needed more time to start. For the com-
parison of planning time between controls and late-stage 
HD patients as well as in the comparison of both groups 
of HD patients for planning time, no significant differences 
were found.
Number of breaks
Figure 4 depicts the total number of breaks for three-, 
four-, five- and six-move problems of the ToL plotted sepa-
rately for the two patient groups and for the three groups. 
To determine the effect of HD disease severity on num-
ber of breaks during the ToL task, an ANOVA was per-
formed on number of breaks with Difficulty as a within-
subjects variable and Group as a between-groups variable. 
This analysis revealed significantly main effects of Diffi-
culty [F(3,249) = 27.36, p < .001] and Group [F(2) = 5.57, 
p = .005]. Furthermore, we calculated the total number of 
breaks across all the four difficulty conditions.
For the comparison between controls and early-stage 
HD patients as well as for the comparison between late- 
and early-stage HD patients, there were no differences in 
the number of brakes in three-, four-, five- and six-move 
problems. For the comparison between controls and late-
stage HD patients, late-stage HD patients differed signifi-
cantly from controls [Tukey, p = .04].
Correlations
To explore whether within the groups of early-stage and 
late-stage HD patients there was any relationship between 
task performance and disease parameters, correlations 
were calculated between total number of solved problems, 
Fig. 3  Total planning time for 
three-, four-, five- and six-move 
problems, plotted separately for 
late-stage HD patients, early-
stage HD patients and controls. 
Error bars represent standard 
errors. Asterisks indicate where 
the comparison between the 
groups was significant. *p < .05
Fig. 4  Number of breaks for 
three-, four-, five- and six-move 
problems, plotted separately for 
late-stage HD patients, early-
stage HD patients and controls. 
Error bars represent standard 
errors. Asterisks indicate where 
the comparison between the 
groups was significant. *p < .05
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total planning time, total number of breaks and the main 
clinical and demographic measures (age, years of educa-
tion, disease duration, genetic burden score, CAG repeats, 
MMSE, premorbid IQ, UHDRS motor scale, UHDRS cog-
nitive scores, TFC). Parametric correlation coefficients 
(Pearson’s r) were calculated; significance was assessed 
using a 2-tailed test. Table 2 shows the significant cor-
relations of late-stage and early-stage HD patients. For 
the group of early-stage HD patients, the total number 
of solved problems was significantly positively corre-
lated with MMSE, premorbid IQ, and UHDRS cognitive 
score and negatively correlated with disease duration and 
UHDRS motor score, indicating the less patients were 
handicapped from their disease the better they scored on 
the ToL. For the group of late-stage HD patients, the total 
number of solved problems was significantly positively 
correlated with the UHDRS cognitive score, indicating the 
more problems patients solved on the ToL the better they 
scored on the cognitive UHDRS. Total planning time was 
positively correlated with total number of solved problems 
and total number of breaks and negatively correlated with 
the UHDRS motor scale. All other associations were small 
and nonsignificant.
For the group of controls, the total number of solved 
problems was significantly positively correlated with years 
of education and negatively correlated with age indicating 
that controls scored better with more years of education 
and with younger age. Total planning time was negatively 
correlated with age, and total number of breaks was nega-
tively correlated with the number of solved problems. All 
other associations were nonsignificant.
Discussion
In this study, we investigated differences in executive sub-
domains between early- and late-stage HD patients com-
pared to healthy controls.
In terms of accuracy of problem solving, controls 
showed better performance relative to early-stage HD 
patients, and early-stage HD patients showed better per-
formance compared to late-stage HD patients. In contrast, 
for the planning time as well as the mean number of breaks 
taken during performance of the ToL, there were significant 
differences between controls and late- and early-stage HD 
patients. However, there were no significant differences 
between late- and early-stage HD patients. Furthermore, 
the total planning time of late-stage HD patients did not 
increase as the difficulty of the ToL conditions went up but 
remained constant throughout the test.
Accuracy, evaluated with total number of solved prob-
lems, is worse in late-stage HD patients compared to 
early-stage HD patients. Unschuld [19] and Watkins [18] 
both reported significantly impaired accuracy in their 
studies of ToL performance in early-stage HD patients 
compared to controls, which was also found in the cur-
rent study. Significant differences of accuracy between 
early- and late-stage HD patients might be related to neu-
ronal cell changes and cell death in the dorsolateral cau-
date head. In patients with HD, apoptosis in the caudate 
proceeds from dorsal to ventral and from medial to lateral 
with the earliest changes being seen in the medial para-
ventricular caudate, caudate tail, and dorsal putamen [25]. 
Indeed, those striatal structures are closely connected 
with the cortex via five parallel loops called the corticos-
triatal circuits [8]. It follows that the associative circuit, 
between the dorsolateral caudate (which degenerates in 
early stages of the disease) and the dorsolateral prefrontal 
cortex (DLPFC), is dysfunctional in the early course of 
the disease, while other circuits like the orbitofrontal cir-
cuit and the limbic circuit remain intact until more severe 
stages. In imaging studies of ToL performance in healthy 
controls, the DLPFC is recruited [26, 27]; accordingly 
early damage of the DLPFC may specifically lead to the 
progressive dysfunction of accuracy typically seen. Accu-
racy, being better in early-stage HD as in late-stage HD 
Table 2  Correlation matrix showing the significant associations of late-stage and early-stage patients’ characteristics with performance on the 
Tower of London
For all of correlations Pearson’s r was employed
Late-stage HD Early-stage HD
Total number of solved problems Total planning time Total number of solved problems
Disease duration NS NS −.43
MMSE NS NS .68
Premorbid IQ NS NS .53
UHDRS motor scale NS −.42 −.59
UHDRS cognitive score .60 NS .65
Total number of solved problems NS .48 NS
Total number of breaks NS .52 NS
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patients, does not seem to be influenced or compensated 
by other neuropsychological functions or brain changes. 
In early-stage HD patients, accuracy correlated with dis-
ease parameters like the MMSE scores and the scores on 
the UHDRS motor and cognitive scales. Subsequently, 
testing of accuracy during the ToL is a predictor for the 
specific cognitive function in early-stage HD patients. 
However, in late stages of HD the only significant rela-
tionship was found between accuracy and the cognitive 
scale score, all other correlations, which are seen in early-
stage HD patients, were not detected. Therefore, in late-
stage HD patients the number of solved problems on the 
ToL is no indicator for most of the clinical changes.
Patients’ and controls’ planning time was recorded 
from the moment of presentation of the start board and the 
goal board to the first movement; all participants had the 
instruction not to start until they had found the right solu-
tion for the problem. While healthy controls and early-
stage HD patients subsequently required more time as task 
difficulty increased, the planning time (in other studies also 
called reaction time or latency) of patients in late stages 
of HD remained stable. This effect of the ToL is also seen 
in other patients with frontal pattern lesions [28–30] like 
in patients with Parkinson’s disease. The stable planning 
time in late-stage HD patients is explained by the develop-
ment of impulsive behaviour during the course of the dis-
ease. Impulsivity and disinhibition are commonly found 
in HD patients [31–33], predominantly in later stages of 
the disease. This effect is also seen in other neuropsycho-
logical tests like the Stroop test: on this task HD patients 
regularly show impairment of impulsivity and disinhibition 
[29]. For the current study, it appears that patients in late 
stages are not able to control their impulsivity anymore, 
accordingly they start too early with the task before they 
have found the right solution. This is in agreement with 
the significantly higher number of breaks of late-stage HD 
patients compared to controls during six-move problems. 
Due to their impulsivity, late-stage patients start too early 
with the ToL and accordingly need more breaks to reflect 
the problem and solution once more. Furthermore, the cur-
rent findings are supported by the positive correlation of 
total planning time with the total number of solved prob-
lems, indicating that late-stage patients who were able to 
suppress their impulsivity had a longer planning time and 
could consecutively solve more problems. Also in clinical 
practice, some late-stage HD patients manage to suppress 
their increasing impulsive behaviour and are able to carry 
out their activities of daily living without a major prob-
lem. Another behavioural problem commonly seen in HD 
patients in late stages is mental slowness. Even though we 
had expected to find influences of mental slowness in the 
assessment of planning time, this behavioural effect could 
not be displayed by our findings. In our study, the effects 
of impulsivity and disinhibition seem to outweigh those of 
mental slowness. As planning time reflects effects of impul-
sivity as well as mental slowness, both parameters cannot 
be disentangled. Regarding the assessment of planning 
time in early-stage HD patients, it appears that they are still 
able to control their impulsivity and manage to adhere to 
instructions given previously.
Early-stage HD patients only showed a significantly 
shorter planning time than controls for three-move prob-
lems. Also the ToL study of Unschuld and colleagues 
reported no significant difference between the plan-
ning times of early-stage affected patients, asymptomatic 
patients and controls [19]; additionally Watkins and col-
leagues did not find a significantly longer planning time 
for early-stage HD patients [18] when one-movement prob-
lems were excluded from the analysis. Summing up, the 
results of early- and late-stage HD patients vary in execu-
tive sub-domains.
Limitations
In our study, all HD patients remained on their usual phar-
macological treatment. As this study was mainly focusing 
on clinical features of HD, we chose to include patients on 
their usual treatment regimens to get a naturalistic depic-
tion of reality.
None of the early-stage HD patients and two of late-
stage HD patients took antipsychotics, and nine of early-
stage HD patients and two of late-stage HD patients took 
antidepressants at the time of testing. Eighteen late-stage 
HD patients and one early-stage HD patient took both.
The findings of antipsychotics producing brain volume 
changes are controversial, and heir influence on brain vol-
umes is still under debate. A review of Roiz-Stantianez 
[34], which included 41 MRI studies in schizophrenia, 
could not find a linear relationship between antipsychotic 
exposure and progressive brain changes. Up to now, it 
remains unclear whether basal ganglia volume changes 
in patients who are treated with antipsychotics are due to 
the underlying disease (for example schizophrenia) or due 
to antipsychotic treatment [34, 35]. For Huntington’s dis-
ease, to our knowledge, there are no studies which show 
acceleration of striatal volume decline under antipsychotic 
treatment. Moreover, we cannot rule out that antipsychotic 
treatment affected the executive sub-domains measured in 
our study as they are known to influence cognitive func-
tions [36]. This has to be taken into careful consideration 
when interpreting our results.
Furthermore, our study results yield no information about 
the progression of executive dysfunctions in individuals, as we 
did not test the same patients during the course of the disease.
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Conclusion
Not all sub-domains of executive dysfunction in late-stage 
HD are reflected by early-stage HD pathology. Accord-
ingly, studies conducted on cognitive function of presymp-
tomatic patients and patients in early stages are not trans-
ferrable to patients in late stages. Furthermore, the current 
study is in line with former results, which suggested that 
the development of cognitive decline is not always com-
parable with that of topographical changes of the striatum. 
Our study has clinical implications because goal-directed 
behaviours in daily life rely on executive processes. Knowl-
edge about the characteristics of executive dysfunction 
sub-domains in late- and early-stage HD will provide better 
advice to caregivers and patients.
Further studies on the development of frontal patterns 
in more advanced HD patients are needed to gather further 
insight into the complex system of changes of executive 
functions during the course of HD.
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in the 1964 Declaration of Helsinki and its later amend-
ments. All participants gave their informed consent prior to 
their inclusion in the study.
Acknowledgments Open access funding provided by Medical Uni-
versity of Graz. We express our kind appreciation to all the partici-
pants of the study.
Compliance with ethical standards 
Conflict of interest On behalf of all authors, the corresponding author 
states that there is no conflict of interest associated with this publica-
tion and there has been no financial support for this work which could 
have influenced its outcome.
Ethical approval Our study has been approved by the ethics com-
mittee of the Medical University of Graz and has therefore been per-
formed in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki and its later amendments.
Informed consent All participants gave their informed consent prior 
to their inclusion in the study.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Cavallo M, Cavanna AE, Harciarek M, Johnston H, Ostacoli L, 
Angilletta C (2013) “Keep up the good work!”: a case study of 
the effects of a specific cognitive training in Alzheimer’s disease. 
Neurocase 19(6):542–552
 2. Borghi M, Cavallo M, Carletto S, Ostacoli L, Zuffranieri M, 
Picci RL, Scavelli F, Johnston H, Furlan PM, Bertolotto A (2013) 
Presence and significant determinants of cognitive impairment in 
a large sample of patients with multiple sclerosis. PLoS ONE 
8(7):e69820
 3. Cavallo M, Adenzato M, MacPherson SE, Karwig G, Enrici I, 
Abrahams S (2011) Evidence of social understanding impair-
ment in patients with amyotrophic lateral sclerosis. PLoS ONE 
6(10):e25948
 4. Ransome MI, Renoir T, Hannan AJ (2012) Hippocampal neuro-
genesis, cognitive deficits and affective disorder in Huntington’s 
disease. Neural Plast 2012:874387. doi:10.1155/2012/874387
 5. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, 
Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, 
Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, 
Landwehrmeyer B, Stout JC, Investigators T-H (2009) Bio-
logical and clinical manifestations of Huntington’s disease in 
the longitudinal TRACK-HD study: cross-sectional analysis 
of baseline data. Lancet Neurol 8(9):791–801. doi:10.1016/
S1474-4422(09)70170-X
 6. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, 
Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Crau-
furd D, Reilmann R, Stout JC, Langbehn DR, Investigators T-H 
(2013) Predictors of phenotypic progression and disease onset in 
premanifest and early-stage Huntington’s disease in the TRACK-
HD study: analysis of 36-month observational data. Lancet Neu-
rolgy 12(7):637–649. doi:10.1016/S1474-4422(13)70088-7
 7. Paulsen JS (2011) Cognitive impairment in Huntington disease: 
diagnosis and treatment. Curr Neurol Neurosci Rep 11(5):474–
483. doi:10.1007/s11910-011-0215-x
 8. Gamdrs PL (1986) Parallel organization of functionally linking 
basal ganglia and cortex. Ann Rev Neurosci 9:357–381
 9. Kloppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen 
JS, Kienzle W, Tabrizi SJ, Ashburner J, Frackowiak RS, Group 
P-HIotHS (2009) Automatic detection of preclinical neurode-
generation: presymptomatic Huntington disease. Neurology 
72(5):426–431. doi:10.1212/01.wnl.0000341768.28646.b6
 10. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner 
E, Andreasen NC, Nopoulos PC (2006) Brain structure in pre-
clinical Huntington’s disease. Biol Psychiatry 59(1):57–63. 
doi:10.1016/j.biopsych.2005.06.003
 11. van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Lang-
behn DR, Scahill RI, Tabrizi SJ, van Buchem MA, van der 
Grond J, Roos RA, Group T-HI (2011) Early atrophy of palli-
dum and accumbens nucleus in Huntington’s disease. J Neurol 
258(3):412–420. doi:10.1007/s00415-010-5768-0
 12. Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF (2008) 
Magnetic resonance imaging as an approach towards identifying 
neuropathological biomarkers for Huntington’s disease. Brain 
Res Rev 58(1):209–225. doi:10.1016/j.brainresrev.2008.04.001
 13. Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, 
Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn 
DR, Johnson SA, Biglan KM, Aylward EH (2011) Neurocogni-
tive signs in prodromal Huntington disease. Neuropsychology 
25(1):1–14. doi:10.1037/a0020937
 14. Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA 
(2013) A review of cognition in Huntington’s disease. Front 
Biosci 5:1–18
 15. Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC (2014) The 
cognitive burden in Huntington’s disease: pathology, phenotype, 
and mechanisms of compensation. Mov Disord 29(5):673–683. 
doi:10.1002/mds.25864
 16. Beste C, Saft C, Gunturkun O, Falkenstein M (2008) 
Increased cognitive functioning in symptomatic Huntington’s 
671Eur Arch Psychiatry Clin Neurosci (2016) 266:663–671 
1 3
disease as revealed by behavioral and event-related potential 
indices of auditory sensory memory and attention. J Neurosci 
28(45):11695–11702. doi:10.1523/JNEUROSCI.2659-08.2008
 17. Tucha OLKW (2004) Turm von London-Deutsche Version. 
Hogrefe Verlag, Göttingen
 18. Watkins LH, Rogers RD, Lawrence AD, Sahakian BJ, Rosser 
AE, Robbins TW (2000) Impaired planning but intact decision 
making in early Huntington’s disease: implications for specific 
fronto-striatal pathology. Neuropsychologia 38(8):1112–1125
 19. Unschuld PG, Liu X, Shanahan M, Margolis RL, Bassett SS, 
Brandt J, Schretlen DJ, Redgrave GW, Hua J, Hock C, Read-
ing SA, van Zijl PC, Pekar JJ, Ross CA (2013) Prefrontal 
executive function associated coupling relates to Hunting-
ton’s disease stage. Cortex 49(10):2661–2673. doi:10.1016/j.
cortex.2013.05.015
 20. Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, 
Roos RA, Leavitt BR, Papoutsi M, Landwehrmeyer GB (2015) 
Compensation in preclinical Huntington’s disease: evidence 
from the track-on HD study. EBioMedicine 2(10):1420–1429
 21. Shoulson I, Fahn S (1979) Huntington disease: clinical care and 
evaluation. Neurology 29(1):1–3
 22. Group THS (1996) Unified Huntington’s Disease Rating Scale: 
reliability and consistency. Huntington Study Group. Mov Dis-
ord 11(2):136–142. doi:10.1002/mds.870110204
 23. Lehrl S, Triebig G, Fischer B (1995) Multiple choice vocabulary 
test MWT as a valid and short test to estimate premorbid intel-
ligence. Acta Neurol Scand 91(5):335–345
 24. Shallice T (1982) Specific impairments of planning. Philos Trans 
R Soc Lond B Biol Sci 298(1089):199–209
 25. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Rich-
ardson EP Jr (1985) Neuropathological classification of Hunting-
ton’s disease. J Neuropathol Exp Neurol 44(6):559–577
 26. Owen AM, Doyon J, Petrides M, Evans AC (1996) Planning and 
spatial working memory: a positron emission tomography study 
in humans. Eur J Neurosci 8(2):353–364
 27. Baker SC, Rogers RD, Owen AM, Frith CD, Dolan RJ, Frack-
owiak RS, Robbins TW (1996) Neural systems engaged by 
planning: a PET study of the Tower of London task. Neuropsy-
chologia 34(6):515–526
 28. Lezak MD (1995) Neuropsychological assessment. Oxford Uni-
versity Press, New York
 29. Holl AK, Wilkinson L, Tabrizi SJ, Painold A, Jahanshahi M 
(2013) Selective executive dysfunction but intact risky decision-
making in early Huntington’s disease. Mov Disord 28(8):1104–
1109. doi:10.1002/mds.25388
 30. Srovnalova H, Marecek R, Kubikova R, Rektorova I (2012) The 
role of the right dorsolateral prefrontal cortex in the Tower of 
London task performance: repetitive transcranial magnetic stim-
ulation study in patients with Parkinson’s disease. Exp Brain Res 
223(2):251–257. doi:10.1007/s00221-012-3255-9
 31. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Wang C, Stout 
JC, Ross CA, Aylward E, Carlozzi NE, Queller S (2010) “Fron-
tal” behaviors before the diagnosis of Huntington’s disease and 
their relationship to markers of disease progression: evidence 
of early lack of awareness. J Neuropsychiatry Clin Neurosci 
22(2):196–207. doi:10.1176/appi.neuropsych.22.2.196
 32. Hamilton JM, Salmon DP, Corey-Bloom J, Gamst A, Paulsen JS, 
Jerkins S, Jacobson MW, Peavy G (2003) Behavioural abnormal-
ities contribute to functional decline in Huntington’s disease. J 
Neurol Neurosurg Psychiatry 74(1):120–122
 33. Rosenblatt A, Leroi I (2000) Neuropsychiatry of Huntington’s 
disease and other basal ganglia disorders. Psychosomatics 
41(1):24–30. doi:10.1016/S0033-3182(00)71170-4
 34. Roiz-Santianez R, Suarez-Pinilla P, Crespo-Facorro B (2015) 
Brain structural effects of antipsychotic treatment in schizophre-
nia: a systematic review. Curr Neuropharmacol 13(4):422–434
 35. van Haren NE, Schnack HG, Koevoets MG, Cahn W, Hulshoff 
Pol HE, Kahn RS (2015) Trajectories of subcortical volume 
change in schizophrenia: a 5-year follow-up. Schizophr Res. 
doi:10.1016/j.schres.2015.09.027
 36. Moustafa AA, Garami JK, Mahlberg J, Golembieski J, Keri S, 
Misiak B, Frydecka D (2016) Cognitive function in schizophre-
nia: conflicting findings and future directions. Rev Neurosci 
27(4):435–448. doi:10.1515/revneuro-2015-0060
